Frequently Asked Questions
Who is eligible to participate in the SCiStar study?
This study has completed enrollment. The participants who have received AST-OPC1 will continue to be followed and Lineage Cell Therapeutics, Inc. will provide periodic study results updates at www.lineagecell.com.
What is AST-OPC1?
AST-OPC1 consists of neural cells known as oligodendrocyte progenitor cells, which are produced from human embryonic stem cells. AST-OPC1 was previously tested in the world’s first human clinical trial of a stem cell derived product.
Has AST-OPC1 been tested in previous clinical research?
AST-OPC1 was previously tested in a clinical study of people completely paralyzed from the waist down.
What were the benefits of AST-OPC1 in previous research?
The previous clinical study of AST-OPC1 was designed to evaluate the safety of a single low dose. No clinical benefit was expected or reported from that study.
Is there any data supporting the use of AST-OPC1 to treat spinal cord injury?
Lab studies have shown the cells in AST-OPC1 promote partial repair of damaged spinal cord tissue and some improvement in the ability of some animals to move their back and/or front legs.
Who is sponsoring the SCiStar study?
The SCiStar study for spinal cord injury was sponsored by Asterias Biotherapeutics, Inc. Asterias Biotherapeutics, Inc, was acquired by Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc.) in March of 2019.